In-vitro血栓溶解モデルにおけるせん断流下におけるChandler Loop形成全血栓の線維素溶解の追跡

Executive Industry Relevance

Physiologically relevant in-vitro thrombolysis models are critical for improving predictive confidence in thrombolytic drug discovery and reducing translational failure rates. The RT-FluFF assay enables real-time, quantitative assessment of clot lysis under controlled shear flow, directly addressing the limitations of static assays. This platform supports more informed candidate triage and de-risking at the preclinical stage, enhancing portfolio decision-making.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of thrombolytic mechanisms under physiologically relevant flow conditions.
• Supports functional validation of drug targets by mimicking arterial, venous, and pulmonary environments.
• Improves predictive confidence for candidate selection by aligning in-vitro outputs with in-vivo relevance.

Screening & Assay Development

• Facilitates preparation of standardized, flow-formed clots for reproducible screening workflows.
• Delivers quantitative, real-time lysis measurements for robust compound evaluation.
• Enables assay scalability and platform reuse across diverse thrombolytic agents and flow regimes.

Translational & Preclinical Research

• Aligns in-vitro assay conditions with disease-relevant hemodynamics to improve translational continuity.
• Supports risk-adjusted advancement decisions by providing physiologically meaningful efficacy data.
• Reduces reliance on animal models by increasing the fidelity of preclinical in-vitro testing.

Pipeline & Workflow Integration

The RT-FluFF assay bridges early discovery and preclinical evaluation by providing a high-fidelity, quantitative platform for thrombolytic candidate assessment under controlled flow conditions.

• Discovery Biology: Enables hypothesis testing and mechanistic de-risking by simulating in-vivo clot formation and lysis dynamics.
• Screening: Provides reproducible, quantitative readouts for compound comparison and assay standardization.
• Analytics: Supports continuous and endpoint measurements, facilitating robust statistical analysis of lysis kinetics.
• Translational Research: Enhances biomarker alignment and preclinical continuity by modeling physiologically relevant shear and flow.
• Enterprise Reuse: Offers a flexible, adaptable platform for repeated use across multiple drug discovery programs.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in thrombolytic screening.
• Operational Value: Delivers standardized, reproducible, and scalable assay workflows.
• Strategic Value: Enables better go/no-go decisions and capital efficiency by improving early-stage data quality.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of thrombolytic candidates.

Implementation Considerations

• Requires expertise in hemodynamics, clot biology, and quantitative assay design.
• Needs instrumentation for controlled flow, temperature regulation, and real-time fluorometric detection.
• Demands cross-team standardization of clot formation and digestion protocols.
• Adaptable to various flow rates and clot types to model different vascular conditions.
• Dependent on access to human whole blood and specialized analytical infrastructure.

Biopharma FAQs